Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study

被引:17
|
作者
Yoon, Young Hee [1 ]
Kim, Ha Kyoung [2 ]
Yoon, Hee Seong [3 ]
Kang, Se Woong [4 ]
Kim, June-Gone [1 ]
Park, Kyu Hyung [5 ]
Jo, Young Joon [6 ]
Lee, Joo Yong [1 ]
Lee, Dong Hoon [1 ]
机构
[1] Univ Ulsan, Dept Ophthalmol, Asan Med Ctr, Seoul 138736, South Korea
[2] Hallym Univ, Dept Ophthalmol, Kangnam Sacred Heart Hosp, Seoul, South Korea
[3] St Marys Eye Clin, Pusan, South Korea
[4] Sungkyunkwan Univ, Dept Ophthalmol, Samsung Med Ctr, Seoul, South Korea
[5] Seoul Natl Univ, Dept Ophthalmol, Bundang Hosp, Gyeonggi Do, South Korea
[6] Chungnam Natl Univ Hosp, Dept Ophthalmol, Taejon, South Korea
关键词
Retinal vein occlusion; Macular edema; Duration of symptom; Early treatment; Korean patients; INTRAVITREAL TRIAMCINOLONE; STANDARD-CARE; RISK-FACTORS; BRANCH; EFFICACY; SAFETY;
D O I
10.1007/s10384-014-0305-9
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
To determine the correlation between the duration of macular edema (ME) and visual outcomes among Korean patients with retinal vein occlusion (RVO). Multicenter, interventional case series. Treatment-naive patients (n = 249) with branch or central RVO (BRVO/CRVO) and ME for < 6 months were included. We assessed the correlation between the duration of ME and treatment outcomes including the mean logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA) improvement, the proportion of patients achieving at least a 3-line gain in BCVA, and the mean reduction in central retinal thickness (CRT) at 6 months. One hundred and fifty-six patients with BRVO and 93 patients with CRVO were divided into five groups based on the duration of ME (< 2, 2-4 weeks, 1-2, 2-3, 3-6 months); the mean baseline BCVA and CRT among the groups did not differ significantly. In BRVO, the mean logarithm of the minimum angle of resolution (logMAR) BCVA improvements in the groups were 0.51, 0.32, 0.17, 0.19, and 0.13, respectively (P = 0.002). The respective percentages of at least 3-line gains were 64, 53, 39, 38, and 21 % (P < 0.001). The BCVA didn't significantly improve in CRVO. The decrease in CRT was not correlated significantly with the duration of ME in either disease. Treatment of BRVO as early as 2 weeks after onset of ME enhanced the visual outcome; there was no correlation in the patients with CRVO. This finding supports the current trend favoring early treatment to obtain better visual outcomes in patients with BRVO.
引用
收藏
页码:146 / 154
页数:9
相关论文
共 50 条
  • [31] Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion
    Topcic, Ivana Gardasevic
    Sustar, Maja
    Brecelj, Jelka
    Hawlina, Marko
    Mekjavic, Polona Jaki
    DOCUMENTA OPHTHALMOLOGICA, 2014, 129 (01) : 27 - 38
  • [32] Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study Reply
    Ogura, Yuichiro
    Roider, Johann
    Korobelnik, Jean-Frakcois
    Holz, Frank G.
    Simader, Christian
    Schmidt-Erfurth, Ursula
    Vitti, Robert
    Berliner, Alyson J.
    Hiemeyer, Florian
    Stemper, Brigitte
    Zeitz, Oliver
    Sandbrink, Rupert
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (03) : 608 - 608
  • [33] Ranibizumab 0.5 mg in Asian patients with visual impairment due to macular edema secondary to central retinal vein occlusion: results from the 12-month CAMELLIA study
    Ma, Zhizhong
    Zhu, Liansheng
    Weisberger, Annemarie
    Cheng, Yu
    Liu, Chang
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [35] Short term results of intra-vitreal bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Thapa, R.
    Paudyal, G.
    NEPALESE JOURNAL OF OPHTHALMOLOGY, 2013, 5 (01) : 63 - 68
  • [36] Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study
    Khurana, Rahul N.
    Chang, Louis K.
    Bansal, Alok S.
    Palmer, James D.
    Wu, Chengqing
    Wieland, Mark R.
    OPHTHALMOLOGY RETINA, 2018, 2 (02): : 128 - 133
  • [37] COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONS Results of the Pan American Collaborative Retina Study Group at 24 Months
    Wu, Lihteh
    Fernando Arevalo, J.
    Berrocal, Maria H.
    Maia, Mauricio
    Roca, Jose A.
    Morales-Canton, Virgilio
    Alezzandrini, Arturo A.
    Diaz-Llopis, Manuel J.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (10): : 1396 - 1403
  • [38] Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
    Ogura, Yuichiro
    Korobelnik, Jean-Francois
    Roider, Johann
    Vitti, Robert
    Holz, Frank
    Hiemeyer, Florian
    Stemper, Brigitte
    Zeitz, Oliver
    Sandbrink, Rupert
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [39] Association of Outer Retinal Layer Morphology With Visual Acuity in Patients With Macular Edema Secondary to Retinal Vein Occlusion - A SCORE Study Ancillary Study
    Domalpally, A.
    Peng, Q.
    Danis, R. P.
    Blodi, B. A.
    Scott, I. U.
    Ip, M. S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [40] VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study (vol 97, pg 278, 2013)
    Holz, F. G.
    Roider, J.
    Ogura, Y.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2015, 99 (12) : 1746 - 1746